Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Ovarian Cancer

Presenters

Skerdi HAVIARI

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

S. HAVIARI1, B. Blanchet2, O. COLOMBAN3, L. Venat-Bouvet4, N. Dohollou5, A. Floquet6, C. Louvet7, J. Lotz8, S. Abadie Lacourtoisie9, L. Favier10, M. Fabbro11, N. Bonichon-Lamichhane12, J.E. Kurtz13, P. Follana14, M. Leheurteur15, F. Del Piano16, C.R. ALLIOT17, J. Alexandre18, B. You3, M. TOD19

Author affiliations

  • 1 Emr3738, Faculté de Médecine et Maïeutique Lyon-Sud, 69921 - OULLINS/FR
  • 2 Service De Pharmacologie Ap Hp, Hôpital Cochin, 75014 - Paris/FR
  • 3 Service D'oncologie Médicale, , CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, 69310 - Pierre Bénite/FR
  • 4 Oncologie Médicale, Centre Hospitalier Universitaire Dupuytren, 87042 - Limoges Cédex/FR
  • 5 Oncologie - Radiothérapie, Polyclinique Bordeaux Nord, 33300 - Bordeaux/FR
  • 6 Oncologie Médicale, Institute Bergonié, 33076 - Bordeaux/FR
  • 7 Oncologie Médicale, Institut Mutualiste Montsouris, 75014 - Paris/FR
  • 8 Oncologie Medicale, Hopital Tenon, 75020 - Paris/FR
  • 9 Oncologie Medicale Gynécologique, Centre Paul Papin, 49055 - Angers/FR
  • 10 Oncologie Médicale, Centre Georges François Leclerc, 21079 - Dijon Cédex/FR
  • 11 Parc Euromedecine, Oncologie Médicale, ICM Val d'Aurelle, 34298 - Montpellier/FR
  • 12 Service D’oncologie, Clinique Tivoli, 33000 - Bordeaux/FR
  • 13 Service D'onco Hematologie, CHU Hautepierre, 67200 - Strasbourg/FR
  • 14 Medical Oncology, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 15 Cancerologie Medicale, Centre Henri Becquerel, 76038 - Rouen/FR
  • 16 Chirurgie Gynécologique, Hôpitaux de LEMAN, 74203 - THONON LES BAINS/FR
  • 17 Oncologie Médicale, Hospital Center Alpes Léman, 74130 - Contamine-sur-Arve/FR
  • 18 Unité D'oncologie Médicale, Hôpital Cochin, 75014 - PARIS Cédex/FR
  • 19 Emr 3738, Université Claude Bernard Lyon 1, 6904 - LYON/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3392

Background

Nintedanib is a multikinase inhibitor whose main targets are VEGFR 1/2/3, PDGFR and FGFR1. It is approved for idiopathic pulmonary fibrosis and non-small-cell lung cancer. The randomized phase II CHIVA trial tested it as an add-on to chemotherapy in the neo-adjuvant/adjuvant setting in advanced ovarian cancer eligible for debulking surgery. We report a nintedanib exposure-response relationship in the nintedanib arm.

Methods

Data from 122 pts in the nintedanib arm were available. A population pharmacokinetic model could not be used, due to the sampling schedule (mostly trough concentrations). Therefore, raw serum nintedanib values were used as indicative of exposure. An ascending step-wise multivariate Cox model building strategy was used, without any a priori requirement for exposure to be in the final model, starting from 26 possible predictors. The outcome of interest (response) was overall survival. The existence and optimal value of a threshold was investigated using effect size and model likelihood with different thresholds. HRs and 95% CI are reported for each variable in the final model. Exposure-safety analyses on grade 3-4 and grade 4 adverse events were performed using similar model-building strategies in time-to-event analyses (Cox models) and in per-visit analyses (logistic models). Sensitivity analyses tested the robustness of the findings.

Results

The final model included average serum nintedanib, ECOG status, resection score, histological type, and renal function. The HR for death per extra 30 ng/mL average serum nintedanib was 0.61 (95% CI, 0.41-0.92). The threshold with highest model likelihood and highest effect on survival was around 50-55 ng/mL(100 nM), which is in the range of known IC50 values for nintedanib targets. 75% of pts were below this value, 25% were below 12 ng/mL. No exposure-safety relationships were found.

Conclusions

An exposure-response relationship was found for nintedanib in ovarian cancer. These exploratory results suggest that while it is difficult to maintain consistent nintedanib exposure, survival gains could reward success on that front. Future nintedanib trials may benefit from therapeutic drug monitoring with a threshold trough concentration of 100 nM.

Clinical trial identification

2011-006288-23.

Editorial acknowledgement

Legal entity responsible for the study

ARCAGY-GINECO.

Funding

Boehringer Ingelheim.

Disclosure

N. Dohollou: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Lilly. A. Floquet: Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Roche. C. Louvet: Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Servier; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: MSD. J.E. Kurtz: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Takeda; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: PharmaMar; Travel / Accommodation / Expenses: Tesaro. P. Follana: Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: AstraZeneca; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Tesaro. M. Leheurteur: Speaker Bureau / Expert testimony: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Eisai. J. Alexandre: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self): PharmaMar; Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.